Psychiatr. pro Praxi, 2006; 4: 174-175

Antidepressives and hypnotics of the 3rd generation in the treatment of chronic insomnia

MUDr. Lucie Závěšická
Psychiatrické centrum Praha, 3. LF UK, Praha

According available literature, the incidence of chronic insomnia is around 10 %. The treatment of chronic insomnia consists most frequently of cognitive-behavioral psychotherapy, hypnotics and antidepressives. Recently we have a lot of information from clinical studies that are testing the effectiveness of therapy of antidepressives and hypnotics of the 3rd generation in the indication of chronic insomnia.

Keywords: chronic insomnia, antidepressives, hypnotics of the 3rd generation

Published: August 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Závěšická L. Antidepressives and hypnotics of the 3rd generation in the treatment of chronic insomnia. Psychiatr. praxi. 2006;7(4):174-175.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Allain H, Albustre L. Zolpidem study group and Schuck S. Efficacy and safety of zolpidem administred, ,as needed" in primary insomnia. Results of double-blind, placebo-controlled study. Clin Drug Incest. 2001; 21(6): 391-400. Go to original source...
    2. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005; 56: 332-343. Go to original source... Go to PubMed...
    3. Buysse DJ, Reynolds CF, Kupfer DJ, Thorpy MJ, Bixler E, Manfredi R, Kales A, Vgontzas A, Stepanski E, Roth T, Hauri P, Mesiano D. Clinical Diagnoses in 216 Insomnia Patients Using the International Classification of Sleep Disorders (ICSD), DSM-IV and ICD-10 Categories: A Report from the APA/NIMH DSM-IV Field Trial. Sleep, 1994, 17 (7): 630-637. Go to original source... Go to PubMed...
    4. Cluyds R, Peeters K, Bouyalski I, Lavoisy J. Comparison of continuous versus intermittent administration of zolpidem in chronic insomnia: double-blind, randomized pilot study. J Int Med Res. 1998; 26(1): 13-24. Go to original source... Go to PubMed...
    5. Coleman RM, Roffwarg HP, Kennedy SJ, Guilleminault C, Cinque J, Cohn MA, Karacan I, Kupfer DJ, Lemmi H, Miles LE, Orr WC, Phillips ER, Roth T, Sassin JF, Schmidt HS, Weitzman ED, Dement WC. Sleep-Wake Disorders Based on a Polysomnographic Diagnosis. JAMA, 1982, 247 (7): 997-1003. Go to original source... Go to PubMed...
    6. Gallup Organization: Sleep in America. Princenton, NJ. Gallup Organization; 1991.
    7. Gallup Organization: Sleep in America. Princenton, NJ. Gallup Organization; 1995.
    8. Hajak G, Bandelow B, Zulley J, PittrowD. "As needed" pharmacotherapy combined with stimulus control treatment in chronic insomnia - assessment of novel intervention strategy in primary care setting. Ann Int Clin Psychiatry. 2002; 14(1): 1-7. Go to original source...
    9. Hajak G, Cluydts R, Allain H, Estivill E, Parrino L, Terzano MG, Walsh JK. The challenge of chronic insomnia: is non-nightly hypnotics treatment a feasible alternative? European Psychiatry. 2003; 18(5): 201-208. Go to original source... Go to PubMed...
    10. Hajak G, Cluydts R, Declerc A, Estivill E, Middleton A, Sonka K. Continuous versus non-nightly use of zolpidem in chronic insomnia: results of large-scale, double-blind, randomized, out-patient study. Int Clin Psychopharmacology. 2001; 17: 9-17. Go to original source... Go to PubMed...
    11. Kryger MH, Roth T, Dement WC. Principles and practice of sleep medicine.4th ED. Philadelphia. Elsevier 2005.
    12. Le Bon O, Murphy JR, Staner L, Hoffmann G, Kormoss N, Kentos M, Dupont P, Lion K, Pelc I, Verbanck P. Double-blind, placebo controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations. J Clin Psychopharmacol. 2 003; 23(4): 377-83. Go to PubMed...
    13. Liappas IA, Malitas PN, Dimopoulos NP, Gitsa OE, Lappas AI, Nikolaou ChK, Christodoulou GN. Zolpidem dependence case series: possible neurobiological mechanismus and clinical managment. J Psychopharmacol. 2 003; 17(1): 131-5. Go to PubMed...
    14. Lustberg L, Reynolds CF. Depression and insomnia: question of cause and effect. Sleep Med Rev 2000; 4(3): 253-262. Go to original source... Go to PubMed...
    15. Mashiko H, Niwa SI, Kumashiro H, Kaneko Y, Suzuki S, Numata Y, Horikoshi R, Watanebe Y. Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by depressive state: Dose - finding study with no concomitant of hypnotics agents. Psychiatry and Clinical Neuroscience. 1999; 53: 193-196. Go to original source... Go to PubMed...
    16. Neylan TC, Metzler TJ, Schoenfeld FB, Weiss DS, Lenoci M, Best SR, Lipsey TL, Marmar CR. Fluvoxamine and slep disturbances in postraumatic stress disorder. J Trauma Stress 2001; 14(3): 461-7. Go to original source... Go to PubMed...
    17. Nowell PD, Reynolds CF 3rd, Buysse DJ, Dew MA, Kupfer DJ. Paroxetine in the treatment of primary insomnia: preliminary clinical and electroencephalogram sleep data. J Clin Psychiatry 1999; 60(11): 795. Go to original source... Go to PubMed...
    18. Palomaki H, Berg A, Meririnne E, Kaste M, Lonnqvist R, lehtihalmes M, Lonnqvist J. Complaints of poststroke insomnia and its treatment with mianserin. Cerebrovasc Dis. 2 003; 15(1-2): 56-62. Go to PubMed...
    19. Perlis ML,MeCall WV, Krystal AD,Walsh JK. Long-term, non-nightly administration of zolpidem in the treatment of patients with primary insomnia. J Clin Psychiatry. 2004; 65(8): 1128-37. Go to original source... Go to PubMed...
    20. Poyares D, Pinto LR, Tavares S, Barros-Viera S. Sleep promototers and insomnia. Rev Bras. Psiquiatr. 2005; 27: 1516-1529. Go to original source...
    21. Saletu B, Saletu-Zyhlaz GM. Sleep laboratory studies with trazodone in insomnia related to depression and dysthymia. Čes a slov Psychiat. 2002; 7: 368-376.
    22. Saletu-Zyhlarz GM, Abu-Baker MH, Anderer P, Gruber G, Mandl M. Insomnia in depression differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone. Pro Neuropsychopharmacol Biol Psychiatry. 2002;26(2): 249-260. Go to original source... Go to PubMed...
    23. Saletu-Zyhlarz GM, Abu-Baker MH, Anderer P, Semler B, Decker K. Insomnia related to dysthymia polysomnographic and psychometric comparison with normal controls and acute therapeuthic trials with trazodone. Neuropsychobilogy.2001; 44(3): 139-149. Go to original source... Go to PubMed...
    24. Shen J, Chung SA, Kayumov L, Moller H, Hossain N, wang X, Deb p, Sun F, Huang X, Novak M, Appleton D, Sharpiro CM. Polysomnographic and syptomatological analyses of major depressive disorder patients treated with mirtazapine. Can J Psychiatry. 2006; 51(1): 27-34. Go to original source... Go to PubMed...
    25. Schmith MT, Perlis ML, Park A, Smith MS, Pennington J, Giles DE, Buysse DJ. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002; 159: 5-11. Go to original source... Go to PubMed...
    26. Schwartz T, Nihalani N, Vikr S, Jindal S, Costello A, Muldoon R, Azhar N, Hussein J, Tirmazi S. A comparison of the effectiveness of two hypnotics agents for treatment of insomnia. Int J Psychiatr Nur Res. 2004; 10(1): 1146-50.
    27. Švestka J. Nová psychofarmaka: Mirtazapin, noradrenergní a specificky serotonergní antidepresivum. Psychiatrie 1999.
    28. Švestka J. Psychofarmaka v klinické praxi. Grada 1995.
    29. Theobald DE, Kirsh Kl, Holtsclaw E, Donoghy K, Passik SD. An open-label, crossover trial of mirtazapine (15 and 30 mg) in cancer patients with pain and other distressing symptoms. J Pain Symptom Manage. 2003; 25(1): 7-8. Go to original source...
    30. Wagner J, Wagner ML. Non-benzodiazepines for the treatment of insomnia. Sleep Med Rev. 2000; 4(6): 551-581. Go to original source... Go to PubMed...
    31. Walsh JK, Roth T, Randazzo A, Erman M, Jamies A, Scharf M, Schweitzer PK, Ware JC. Eight weeks of non-nightly use of zolpidem for primary insomnia. Sleep 2 000; 23(8): 1 087-96.
    32. Ware JC, Walsh Jk, Scharf NB, Roehrs T, Roth T, Vogel GW. Minimal rebound insomnia after treatment with 10-mg zolpidem. Clin Neuropharamcol. 1997; 20(2): 116-25. Go to original source... Go to PubMed...
    33. Winocur A, Sateia MJ, Hayes JB, Bayels-Dazet W, MacDonald MM, Gary KA. Acute effects of mirtazapine on slep Continuity and sleep architecture in depressed patiens: a pilot study. Biol Psychiatry. 2000; 48(1): 75-8. Go to original source... Go to PubMed...
    34. Yamandera H, Nakanuta s, Sužuji H, Endo S. Effects of trazodone hydrochloride and imipramine on polysomnography in healthy subjects. Psychiatry Clin Neurosci. 1998; 52(4): 439-443. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.